Financial 2018 marked our return to Product Sales growth Review with strong performance from Growth Platforms and New Medicines more than offsetting the continued impact from patent expiries.
Product sales grew 4% to $21.0 billion driven by outstanding performance of our Oncology medicines: Emerging Markets sales continued to grow: and New CVRM grew by 12% CER:12%.
In 2018, Product Sales grew 4% to $21.0 billion The Reported tax rate of 3 % and Core tax driven by outstanding performance of our rate of 11% for the year benefitted from a Oncology medicines, which grew 50% CER: favourable net adjustment of $0.3 billion to 49%, led by Tagrisso, Lynparza and Imfinzi.
deferred tax, reflecting the recently announced Emerging Markets sales continued to grow, reductions to the Dutch and Swedish income especially in China, and it is now our largest tax rate.
Additionally, there was a $0.2 billion region by total Product Sales.
New CVRM grew benefit to the Reported and Core tax rates 12% CER:12% to $4.0 billion with both Farxiga resulting from a reduction in tax provisions.
and Brilinta delivering sales over $1.3 billion annually.
Total Revenue was $22.1 billion, a 2% Reported operating profit declined by 8% decline led by lower Externalisation Revenue of CER: 7% to $3.4 billion and Core operating $1.0 billion, a 55% reduction from 2017.
In profit decreased by 17% CER: 17% to $5.7 2018, $0.8 billion of Externalisation Revenue billion in the year.
Reported EPS was $1.70 was received as part of our collaboration with and Core EPS was $3.46.
MSD on Lynparza and selumetinib.
We generated a net cash inflow from Reported R&D expenses increased by 3% as a operating activities of $2.6 billion in the year result of higher intangible asset impairment and we maintained a strong, investmentcharges.
Core R&D expenses declined by 3% grade credit rating.
During the year, we issued with focus on resource prioritisation, new bonds totalling $3.0 billion and repaid productivity improvements and improved $1.4 billion of maturing bonds.
We ended the development processes all delivering cost year with total gross debt of $19.1 billion, $6.1 reductions whilst maintaining high levels of billion of cash, investments and derivatives, activity.
Reported SG&A expenses declined by with net debt of $13.0 billion.
2% CER: 3% primarily due to the decrease in fair value of contingent consideration liabilities.
Core SG&A expenses increased by 10% CER: 9% due to commercial and medical affairs support for New Medicines and to drive growth Marc Dunoyer in China.
Chief Financial Officer Reported other operating income was $2.5 billion in the year and included income from various disposal transactions, including the sale of the rights to Nexium in Europe to Grnenthal and the sale of the rights to Seroquel and Seroquel XR in UK, China and other international region markets to Luye Pharma.
74 AstraZeneca Annual Report & Form 20-F Information 2018 Strategic Report Strategic Report Contents The purpose of this Financial Review is to Further details of the risks faced by the Introduction 74 provide a balanced and comprehensive analysis business are given in Risk Overview from Business background of the financial performance of the business page 70 and Risk from page 220. and results overview 75 during 2018, the cash flow and liquidity position Measuring performance 76 of the business, the financial position as at the Over the longer term, the success of our Results of operations end of the year, and the main business factors R&D is crucial and we devote substantial summary analysis of year and trends which could affect the future resources to this area.
The benefits of this ended 31 December 2018 77 financial performance of the business.
investment are expected to emerge over the Cash flow and liquidity for the year ended long-term and there is considerable inherent 31 December 2018 82 Business background and uncertainty as to the scale and timing of Financial position results overview outcomes and their transition to saleable 31 December 2018 83 The business background is covered in the products.
Capitalisation and Marketplace section from page 11, the Therapy shareholder return 86 Area Review from page 50 and describes in The most significant features of our financial Future prospects 86 detail the developments in our products.
results in 2018 are: Financial risk management 86 Critical accounting As described earlier in this Annual Report, Total Revenue down 2% to $22,090 million policies and estimates 87 sales of our products are directly influenced CER: 2%.
Product Sales were up 4% Sarbanes-Oxley Act by medical need and are generally paid for by CER: 4% reflecting the performance of Section 404 90 health insurance schemes or national New Medicines and the ongoing growth in healthcare budgets.
Our operating results can Emerging Markets.
be affected by a number of factors other than Oncology sales increased by 50% the delivery of operating plans and normal CER: 49% with Tagrisso up 95% CER: competition, such as: 93% to $1,860 million, Imfinzi sales The risk of competition from generics reaching $633 million arising primarily in following loss of patent protection or patent the US and Lynparza sales of $647 million expiry of one of our products, or an at risk representing growth of 118% CER: launch by a competitor, or the launch of a 116%, driven by expanded use in the competitive product in the same class as treatment of ovarian cancer and first one of our products, with potential adverse approval in the treatment of breast effects on sales volumes and prices.
of patent expiries for our key marketed New CVRM sales increased by 12% products are included in Patent Expiries CER: 12% to $4,004 million and ofKey Marketed Products from page 217. included Farxiga sales of $1,391 million The adverse impact on pharmaceutical with growth of 30% CER: 30% including prices as a result of the macroeconomic a sales increase of 45% CER: 52% in and regulatory environment.
For instance, Emerging Markets and Brilinta sales of inthe US, political leadership has continued $1,321 million representing growth of to consider drug pricing controls and 22% CER: 21%.
transparency measures at national and Respiratory was up 4% CER: 3% local levels.
In other parts of the world, reflecting growth for Pulmicort and the governments have continued to implement success of the 2017 launch of Fasenra, and expand price control measures, offset by a continued fall in US Product including reference pricing.
The timings of new product launches, which Emerging Markets grew by 12% CER: can be influenced by national regulators, 13% to $6,891 million, making it the the speed to market relative to competitor Groups largest region by Product Sales products and the risk that such new for the first time.
China sales increased products do not succeed as anticipated, by 28% CER: 25% to $3,795 million.
together with the rate of sales growth and Oncology sales in China were up 44% costs following new product launches.
CER: 41% partly underpinned by the Currency fluctuations.
Our functional and 2017 launch of Tagrisso.
reporting currency is the US dollar, but we Reported operating profit was down 8% have substantial exposures to other CER: 7% to $3,387 million 2017: $3,677 currencies, in particular the Chinese million driven by declines in Total Revenue renminbi, euro, Japanese yen, pound and the increase to Reported R&D sterling and Swedish krona.
Macro factors such as greater demand Core operating profit was also down 17% froman ageing population and increasing CER: 17% to $5,672 million 2017: $6,855 requirements of Emerging Markets.
The difference between Core and Supply chain risks including the failure Reported operating profit is largely driven ofthird parties to supply timely quality by the impact of non-core amortisation products, such as raw materials, and the and impairment of intangibles.
The riskof catastrophic failure of critical internal decrease from prior year was driven by processes leading to an inability to research, a credit to core adjustments from the manufacture or supply products to patients.
AstraZeneca Annual Report & Form 20-F Information 2018 Financial Review 75 Financial Review continued Reported operating margin of 15% of Total determining the adjustments to arrive We strongly encourage readers of the Annual Revenue was one percentage point down atthe Core result, we use a set of Report not to rely on any single financial on 2017 CER: one percentage point.
Core established principles relating to the measure but to review our financial operating margin was 26% of Total Revenue nature and materiality of individual items statements, including the notes thereto, 2017: 31%.
or groups of items, excluding, for andour other publicly filed reports, carefully Reported EPS was down 28% CER: 29% example, events which i are outside the and in their entirety.
Core EPS was also down 19% normal course of business, ii are CER: 19% to $3.46.
incurred in a pattern that is unrelated to CER measures allow us to focus on the Dividends paid amounted to $3,484 million the trends in the underlying financial changes in revenues and expenses driven 2017: $3,519 million.
performance of our ongoing business, or byvolume, prices and cost levels relative to iii are related to major acquisitions, to the prior period.
Revenues and cost growth Measuring performance ensure that investors ability to evaluate expressed in CER allow management to The following measures are referred to in this and analyse the underlying financial understand the true local movement in Financial Review when reporting on our performance of our ongoing business is revenues and costs, in order to compare performance both in absolute terms, but more enhanced.
See the 2018 Reconciliation of recent trends and relative return on often in comparison to earlier years: Reported results to Core results table on investment.
CER growth rates can be used the opposite page for a reconciliation of toanalyse revenues in a number of ways but, Reported performance: Reported Reported to Core performance, as well most often, we consider CER growth by performance takes into account all the as further details of the adjustments.
products and groups of products, and by factors including those which we cannot EBITDA is defined as Reported Profit countries and regions.
CER revenue growth influence, such as currency exchange rates before tax plus net finance expense, share can be further analysed into the impact of that have affected the results of our of after tax losses of joint ventures and revenue volumes and selling price.
Similarly, business, as reflected in our Group associates and charges for depreciation, CER cost growth helps us to focus on the real Financial Statements prepared in amortisation and impairment.
Reference local change in costs so that we can manage accordance with IFRSs as adopted by the should be made to the Reconciliation of the cost base effectively.
EU and as issued by the IASB IFRS.
Reported Profit Before Tax to EBITDA Non-GAAP financial measures: Core included on page 78 of this Annual Report.
We believe that disclosing non-GAAP financial financial measures, EBITDA, Net debt, Net debt is defined as interest-bearing and growth measures, in addition to our Ongoing Externalisation Revenue and Initial loans and borrowings net of cash and Reported financial information, enhances Externalisation Revenue are non-GAAP cash equivalents, other investments and investors ability to evaluate and analyse the financial measures because they cannot be net derivative financial instruments.
financial performance and trends of our derived directly from the Group Reference should be made to the Net debt ongoing business and the related key Consolidated Financial Statements.
reconciliation table included on page 82 business drivers.
The adjustments are made Management believes that these non-GAAP of this Annual Report.
to our Reported financial information in order financial measures, when provided in Ongoing Externalisation Revenue is defined to show non-GAAP financial measures that combination with Reported results, will as Externalisation Revenue excluding Initial illustrate clearly, on a year-on-year or provide investors with helpful Externalisation Revenue which is defined period-by-period basis, the impact on our supplementary information to better as Externalisation Revenue that is recognised performance caused by factors such as understand the financial performance and at the point in time control is transferred.
changes in revenues and expenses driven by position of the Group on a comparable Ongoing Externalisation Revenue comprises, volume, prices and cost levels relative to such basis from period to period.
These among other items, milestones, profit prior years or periods.
non-GAAP financial measures are not a sharing and royalties.
Reference should be substitute for, or superior to, financial made to the Externalisation Revenue table Readers of the Annual Report should note that measures prepared in accordance on page 78 of this Annual Report.
Core results cannot be achieved without withGAAP.
Constant exchange rate CER growth incurring the costs that the Core measures Core financial measures are adjusted to rates: These are also non-GAAP measures.
exclude such as: exclude certain significant items, such as: These measures remove the effects of amortisation and impairment of intangible currency movements by retranslating the Amortisation of intangible assets which assets, including impairment reversals but current years performance at the previous generally arise from business combinations excluding any charges relating to IT assets years average exchange rates and and individual licence acquisitions.
We charges and provisions related to our adjusting for other exchange effects, adjust for these charges because their global restructuring programmes, which including hedging.
A reconciliation of the pattern of recognition is largely include charges that relate to the impact Reported results adjusted for the impact of uncorrelated with the underlying of our global restructuring programmes currency movements is provided in the performance of the business.
However, a on our capitalised manufacturing facilities 2018 Reported operating profit table on the significant part of our revenues could not be and IT assets page opposite.
generated without owning the associated other specified items, principally Gross and operating margin percentages: acquired intangible assets.
comprising acquisition-related costs and These measures set out the progression of Charges and provisions related to our credits, which include fair value key performance margins and illustrate the global restructuring programmes which can adjustments and the imputed finance overall quality of the business.
take place over a significant period of time, charge relating to contingent Prescription volumes and trends for key given the long life-cycle of our business.
We consideration on business combinations, products: These measures can represent adjust for these charges and provisions legal settlements and foreign-exchange the real business growth and the progress because they primarily reflect the financial gains and losses on certain nonof individual products better and more impact of change to legacy arrangements, structural intra-group loans.
In immediately than invoiced sales.
rather than the underlying performance of our ongoing business.
However, our Core results do reflect the benefits of such restructuring initiatives.
76 AstraZeneca Annual Report & Form 20-F Information 2018 Strategic Report Strategic Report It should also be noted that other costs Results of operations summary analysis of year ended 31 December 2018 excluded from our Core results, such as 2018 Reported operating profit finance charges related to contingent Reported 2018 consideration will recur in future years and Percentage of compared 2018 2017 Total Revenue with Reported 2017 other excluded items such as impairments Growth and legal settlement costs, along with other due to acquisition-related costs, may recur in CER exchange Reported Reported Actual CER Reported growth effects Reported 2018 2017 growth growth thefuture.
$m $m $m $m % % % % Product Sales 21,049 733 164 20,152 4 4 As shown in the 2018 Reconciliation of Externalisation Revenue 1,041 1,274 2 2,313 55 55 Reported results to Core results table to the right, our reconciliation of Reported financial Total Revenue 22,090 541 166 22,465 2 2 information to Core financial measures Cost of sales 4,936 542 76 4,318 22.3 19.2 14 13 includes a breakdown of the items for which Gross profit 17,154 1,083 90 18,147 77.7 80.8 5 6 our Reported financial information is adjusted, Distribution expenses 331 20 1 310 1.5 1.4 7 6 and a further breakdown by specific line item Research and as such items are reflected in our Reported development expenses 5,932 151 24 5,757 26.9 25.6 3 3 income statement.
This illustrates the Selling, general and significant items that are excluded from Core administrative expenses 10,031 310 108 10,233 45.4 45.5 2 3 financial measures and their impact on our Other operating Reported financial information, both as a income and expense 2,527 697 1,830 11.4 8.1 38 38 whole and in respect of specific line items.
Operating profit 3,387 247 43 3,677 15.3 16.4 8 7 Management presents these results externally Net finance expense 1,281 27 141 1,395 to meet investors requirements for Share of after tax transparency and clarity.
Core financial losses of joint ventures measures are also used internally in the and associates 113 58 55 management of our business performance, Profit before tax 1,993 332 98 2,227 10 14 in our budgeting process and when Taxation 57 574 10 641 determining compensation.
As a result, Core Profit for the period 2,050 906 88 2,868 financial measures merely allow investors to differentiate between different kinds of costs Basic earnings and they should not be used in isolation.
per share $ 1.70 2.37 28 29 Readers should also refer to our Reported financial information in the 2018 Reported 1 As detailed on page 76, CER growth is calculated using prior year actual results adjusted for certain exchange effects operating profit table and our reconciliation including hedging.
of Core financial measures to Reported financial information in the Reconciliation of 2018 Reconciliation of Reported results to Core results Reported results to Core results table, both to Core 2018 the right, for our discussion of comparative compared with Intangible Actual growth measures that reflect all factors Core 2017 amortisation that affect our business.
2018 Restructuring and Diabetes 2018 Actual CER 4 3 Reported costs impairments Alliance Other Core growth growth $m $m $m $m $m $m % % Our determination of non-GAAP measures, Gross profit 17,154 432 187 17,773 4 4 and our presentation of them within this Product Sales financial information, may differ from 2 gross margin % 76.6 79.5 similarlytitled non-GAAP measures of Distribution expenses 331 331 7 6 othercompanies.
Research and development The SET retains strategic management of expenses 5,932 94 572 5,266 3 3 thecosts excluded from Reported financial Selling, general and information in arriving at Core financial administrative measures, tracking their impact on Reported expenses 10,031 181 1,582 60 323 8,651 10 9 operating profit and EPS, with operational Other operating management being delegated on a case-byincome and expense 2,527 10 4 374 2,147 10 10 case basis to ensure clear accountability and Operating profit 3,387 697 2,345 60 697 5,672 17 17 consistency for each cost category.
Operating margin as a % of Total Revenue 15.3 25.7 Net finance expense 1,281 337 208 736 Taxation 57 146 487 73 109 540 Basic earnings per share $ 1.70 0.43 1.47 0.16 0.30 3.46 19 19 1 Each of the measures in the Core column in the above table is a non-GAAP measure.
2 Gross margin as a % of Product Sales reflects gross profit derived from Product Sales, divided by Product Sales.
3 See page 81 for further details of other adjustments.
4 Relating to the 2014 acquisition of BMSs share of Global Diabetes Alliance.
AstraZeneca Annual Report & Form 20-F Information 2018 Financial Review 77 Financial Review continued Total Revenue Reconciliation of Reported Profit Before Tax to EBITDA Total Revenue for the year was down 2% Actual CER CER: 2% to $22,090 million, comprising 2018 2017 growth growth Product Sales of $21,049 million up 4% CER: $m $m % % 4% and Externalisation Revenue of $1,041 Reported profit before tax 1,993 2,227 10 14 million, a decrease of 55% CER: 55%.
Net finance expense 1,281 1,395 8 2 Share of after tax losses of joint ventures By Geography and associates 113 55 104 104 Product Sales in Emerging Markets continued Depreciation, Amortisation and Impairment 3,753 3,036 24 24 to increase with growth of 12% CER: 13% EBITDA 7,140 6,713 6 7 to$6,891 million in 2018, including growth in China of 28% CER: 25% to $3,795 million.
Sales of Tagrisso in Emerging Markets increased by $212 million in the year to $347 Growth Platforms million, an increase of 157% CER: 159%.
2018 2017 Actual CER USProduct Sales were up 11% CER: 11% Product Sales Product Sales growth growth $m $m % % to$6,876 million, reflecting the success of thenew Oncology medicines and the strong Emerging Markets 6,891 6,149 12 13 performance of Fasenra.
In Europe, Product Respiratory 4,911 4,706 4 3 Sales declined by 6% CER: 10% to $4,459 1 New CVRM 4,004 3,567 12 12 million, reflecting the continued impact from Japan 2,004 2,208 9 11 generic competition on Crestor.
Established Oncology 6,028 4,024 50 49 Markets sales declined 8% CER: 9% to 3 Total Growth Platform Product Sales 18,464 16,396 13 12 $2,823 million with sales in Japan down 9% CER: 11% to $2,004 million largely driven by 1 New Cardiovascular, Renal & Metabolic Diseases, incorporating Brilinta and Diabetes.
the decline in Crestor sales, which declined by 2 Oncology comprises total Oncology Product Sales.
3 66% CER: 67% to $166 million in the year as Certain Product Sales are included in more than one Growth Platform.
Total Growth Platform sales represents the net total sales for all Growth Platforms.
the impact of generic competition from 2017 took effect.
Externalisation Revenue By Product 2018 2017 Our largest selling products in 2018 were $m $m Symbicort $2,561 million, Tagrisso $1,860 Externalisation Revenue Initial million, Nexium $1,702 million and Crestor Crestor Almirall 61 $1,433 million.
Global sales of Symbicort Lynparza selumetinib MSD 997 declined by 9% CER: 10% with 13% growth Zoladex TerSera 250 in Emerging Markets CER: 14% being more MEDI8897 Sanofi 127 than offset by declines in US and Europe due Other 51 118 to the impact of a competitive environment on net pricing.
Tagrisso sales grew by 95% CER: Total Initial Externalisation Revenue 112 1,492 93% reflecting strong market penetration Ongoing Externalisation Revenue following 2017 approvals in US and China.
Lynparza selumetinib MSD option exercised 400 250 Nexium sales were down 13% CER: 14% Lynparza selumetinib MSD milestone 390 reflecting continued lower demand as a result Zoladex TerSera milestone 35 of the loss of exclusivity from 2015, however the decline in sales has been slower than Global non-US anaesthetics portfolio Aspen milestone 150 expected.
Crestor sales declined by 39% brodalumab Valeant milestone 130 CER: 40% as the impact of generic AZD3293 Lilly milestone 50 competition continued to take effect.
There Royalties 49 108 were also continued strong performances in Other 55 133 the year from Farxiga and Brilinta, with Farxiga Total Ongoing Externalisation Revenue 929 821 growing by 30% CER: 30% and Brilinta by 22% CER: 21%.
Total Externalisation Revenue 1,041 2,313 78 AstraZeneca Annual Report & Form 20-F Information 2018 Strategic Report Strategic Report Growth Platforms Externalisation Revenue monotherapies or combination therapies will In the periods under review, our Growth Details of our significant business be shared equally.
MSD will fund all Platforms included products in our three main development transactions which give rise development and commercialisation costs of therapy areas, and a focus on the Emerging toExternalisation Revenue are given below: Keytruda in combination with Lynparza or Markets and Japan.
AstraZeneca will fund all grew by 13% CER: 12%, representing 84% of In November 2018, AstraZeneca entered development and commercialisation costs of Total Revenue after removing the effect of intoan agreement with Swedish Orphan Imfinzi in combination with Lynparza or certain Product Sales which are included in Biovitrum AB Sobi to sell the US rights to selumetinib.
AstraZeneca will continue to more than one Growth Platform.
Under the agreement Sobi will also manufacture Lynparza and selumetinib.
As have the right to participate in AstraZenecas part of the agreement, MSD will pay Product Sales in Emerging Markets grew by share of US profits and losses related to AstraZeneca up to $8.5 billion in total 12% compared to 2017 CER: 13% to $6,891 MEDI8897.
The deal was completed on 23 consideration, including $1.6 billion upfront, million partly driven by a strong performance January 2019 and AstraZeneca received an $750 million for certain licence options and from Tagrisso with growth of 157% CER: upfront consideration of $1.6 billion, including up to $6.2 billion contingent upon successful 159%.
Product Sales in China increased by cash of $966 million and ordinary shares in achievement of future regulatory and sales 28% in 2018 CER: 25%, representing 55% of Sobi with an initial market value of $600 milestones.
Of the upfront payment of $1.6 Emerging Markets Product Sales in the year.
This income was recorded in 2019. billion, $1.0 billion was recognised as AstraZeneca will also receive up to $470 Externalisation Revenue on deal completion Product Sales of Respiratory medicines million in sales-related payments for Synagis, in 2017, with the remaining $0.6 billion increased by 4% CER: 3%, with the impact of $175 million following the submission of the deferred to the balance sheet.
AstraZeneca pricing pressure in the US for Symbicort being Biologics License Application BLA for will book all Product Sales of Lynparza and more than offset by a strong performance by MEDI8897, potential net payments of $110 selumetinib: gross profits due to MSD under Respiratory in Emerging Markets and higher million for other MEDI8897 profit-related the collaboration will be recorded under demand for Pulmicort in China.
milestones and $60 million in non-contingent Cost of Sales.
payments for MEDI8897 during the period In November 2017, MSD exercised the first New CVRM grew by 12% CER: 12% with from 2019 to 2021. licence option resulting in Externalisation revenue of $4,004 million 2017: $3,567 In December 2017, AstraZeneca entered Revenue of $250 million.
Within New CVRM, sales of Brilinta in into an agreement effective January 2018 In January 2018, the FDA expanded the the year were $1,321 million, an increase of with Almirall, under which Almirall is granted approved use of Lynparza to include the 22% CER: 21%.
Brilinta sales in the US were an exclusive and perpetual licence to treatment of patients with certain types of up 16% to $588 million, as it remained the distribute and undertake certain breast cancer.
The approval triggered a $70 branded oral anti-platelet market leader.
manufacturing activities related to Crestor million milestone payment from MSD to and Provisacor in Spain.
Our Diabetes Product Sales were 8% higher upfront payment of 51 million on In June 2018, net sales of Lynparza reached than in 2017, driven primarily by growth of completion of the deal and will pay $250 million cumulative sales threshold, 30% on Farxiga CER: 30% with global sales additional sales-related milestones of up to triggering a sales-related milestone of $100 of $1,391 million as it continued to be our 55 million plus a royalty for ten years.
million to fall due to AstraZeneca.
largest-selling Diabetes medicine and SGLT-2 In July 2017, the Group announced a global In November 2018, MSD exercised the class growth was supported by growing strategic oncology collaboration with MSD second licence option resulting in evidence around cardiovascular benefits, to co-develop and co-commercialise Externalisation Revenue of $400 million.
In including data from the CVD-REAL study that AstraZenecas Lynparza for multiple cancer addition to the exercise of this option, net was published in March 2017. types.
Under the collaboration, the sales of Lynparza reached the $500 million companies will develop and commercialise cumulative sales threshold, triggering a Japan Product Sales declined by 9% CER: Lynparza jointly, both as monotherapy and in sales-related milestone of $150 million to 11% with growth on Tagrisso and Forxiga, combination with other potential medicines.
outweighed by the impact of the entry of AstraZeneca and MSD will also jointly In December 2018, AstraZeneca was notified generic competition to Crestor in 2017. develop and commercialise AstraZenecas of an FDA approval of Lynparza, which selumetinib, an oral, potent, selective triggered the SOLO-1 $70 million milestone Product Sales of Oncology medicines inhibitor of MEK, part of the mitogenpayment to AstraZeneca.
increased to $6,028 million in 2018 2017: activated protein kinase MAPK pathway, In March 2017, AstraZeneca announced an $4,024 million, $1,860 million of which came currently being developed for multiple agreement to develop and commercialise from Tagrisso 2017: $955 million, which indications including thyroid cancer.
Under the continues to be our leading medicine for the Independently, AstraZeneca and MSD will terms of the global agreement, Sanofi treatment of lung cancer and received develop and commercialise Lynparza in made an upfront payment of 120 million regulatory approval in more than 55 countries combination with their respective PD-L1 and and will pay up to 495 million upon by the end of 2018.
Under achievement of certain development and the terms of the agreement, the two sales-related milestones.
All costs and companies will share the development and profits are shared equally.
The US element commercialisation costs for Lynparza and of this collaboration is the subject of a selumetinib monotherapy and non-PD-L1 participation agreement with Sobi, entered PD-1 combination therapy opportunities.
into in November 2018 and effective Gross profits from Lynparza and selumetinib 23January 2019.
Product Sales generated through AstraZeneca Annual Report & Form 20-F Information 2018 Financial Review 79 Financial Review continued In March 2017, AstraZeneca entered into an million for the licence $155 million in 2016 Reported SG&A expenses decreased by 2% agreement with TerSera for the commercial and a further $155 million in 2017.
CER: 3% to $10,031 million primarily due to rights to Zoladex in the US and Canada.
In September 2015, AstraZeneca the revaluation of contingent consideration TerSera paid $250 million upon completion announced that the Group had entered into liabilities arising on business combinations.
The Group will also a collaboration agreement with Valeant Core SG&A expenses increased by 10% receive sales-related income through under which AstraZeneca granted an CER: 9% to $8,651 million reflecting milestones totalling up to $70 million, as exclusive licence to Valeant to develop and investment in the launch of new medicines.
well as recurring quarterly sales-based commercialise brodalumab, except in payments at mid-teen percent of Product Japan and certain other Asian countries.
Reported Other operating income and expense Sales.
AstraZeneca will also manufacture Valeant assumed all development costs in the year was up 38% CER: 38% at $2,527 and supply Zoladex to TerSera, providing a associated with the regulatory approval for million which includes $695 million from the further source of ongoing income from brodalumab.
Under the terms of the sale of the rights to Nexium in Europe to Zoladex in the US and Canada.
In agreement, Valeant made an upfront Grnenthal, $527 million on the sale of the December 2018, TerSera paid a salespayment to AstraZeneca of $100 million in rights to Seroquel and Seroquel XR in UK, related milestone of $35 million to 2015.
The agreement also included China and other international region markets to AstraZeneca.
pre-launch milestones of up to $170 million Luye Pharma, $210 million from the sale of In October 2016, the Group announced an and further sales-related milestone rights to Atacand in Europe to Cheplapharm, agreement with Aralez for the rights to the payments of up to $175 million.
After milestone receipts of $172 million from the branded and authorised generic marketed approval, profits would be shared between disposal of the anaesthetics portfolio outside by Par Pharmaceuticals for Toprol-XL Valeant and AstraZeneca.
In February 2017, the US to Aspen, and $139 million from the sale metoprolol succinate in the US.
Aralez paid the FDA approved brodalumab injection for of global rights to Alvesco, Omnaris and $175 million upon completion of the the treatment of adult patients with Zetonna to Covis.
As these elements of our transaction.
Aralez will also pay up to $48 moderate-to-severe plaque psoriasis who income arose from product divestments, where million in milestone and sales-related are candidates for systemic therapy or we no longer retain significant ongoing payments, as well as mid-teen percentage phototherapy and have failed to respond or economic interest, in accordance with our royalties on Product Sales.
AstraZeneca lost response to other systemic therapies, Externalisation Revenue definition in the continues to manufacture and supply triggering a milestone payment of $130 Accounting Policy note on page 155 and the Toprol-XL and the authorised generic million to AstraZeneca.
requirements of IFRS 15 Revenue from medicine to Aralez.
In May 2018, Aralez Contracts with Customers, proceeds from announced a change in strategic direction As detailed in Risk from page 220, the these divestments are recorded as other and the closure of their US commercial development of any pharmaceutical product operating income.
operations and this was followed shortly candidate is a complex and risky process that afterwards by an announcement that they may fail at any stage in the development Reported operating profit declined by 8% had formally moved in bankruptcy process due to a number of factors including CER: 7% to $3,387 million in the year.
A provision of $14 million has items such as failure to obtain regulatory Reported operating margin declined by one been recorded for overdue receivables.
approval, unfavourable data from key studies, percentage point CER: one percentage point In June 2016, AstraZeneca announced that adverse reaction to the product candidate or to 15% of Total Revenue.
The decrease was it had entered into a commercialisation indications of other safety concerns.
The primarily driven by declines in Total Revenue agreement with Aspen for rights to its potential future milestones quoted above are and Reported gross margin as well as the global anaesthetics portfolio outside the subject to these risks.
aforementioned increase in Reported R&D US.
The agreement covers seven expenses.
Core operating profit declined by established medicines Diprivan, EMLA Gross margin, operating margin and 17% CER:17% in the year to $5,672 million.
and five local anaesthetics Xylocaine, earnings per share The Core operating profit margin decreased by Marcaine, Naropin, Carbocaine and Reported gross profit declined by 5% CER: five percentage points to 26% of Total Revenue.
Under the terms of the 6% to $17,154 million.
Core gross profit agreement, Aspen acquired the declined by 4% CER: 4% to $17,773 million.
Reported net finance expense decreased by commercialisation rights for an upfront The declines primarily reflected the lower level 8% CER: increased 2% in the year to $1,281 consideration of $520 million.
In July 2017, of Externalisation Revenue and an adverse million 2017: $1,395 million reflecting the Aspen achieved the first Product Sales impact from an increase in the Cost of Sales.
effect of higher Net debt and an adverse related payment milestone triggering a The difference between Reported and Core movement in the fair value of bonds and payment to AstraZeneca of $150 million.
In Gross Margin arose predominantly on the derivative instruments and offset by lower September 2017, AstraZeneca announced $0.3 billion restructuring costs associated levels of discount unwind on Acerta Pharma that it had entered into an agreement with with the impairment of site-related assets and liabilities.
Core net finance expense increased Aspen, under which Aspen acquired the inventory from the US Biologics site closures by 13% CER: 11% in the year to $736 million.
residual rights to the seven established in Longmont and Boulder, CO. anaesthetics medicines.
This new Reported profit before tax declined by 10% agreement completed in October 2017 and Reported R&D expenses in the year increased CER: 14% in the year to $1,993 million 2017: income under this arrangement is now by 3% CER: 3% to $5,932 million as a result of $2,227 million, reflecting the lower level of recorded in Other operating income and increased intangible asset amortisation and Externalisation Revenue, lower Reported expense, in line with our definition of impairment.
Intangible asset impairment gross margin and the increase in Reported Externalisation Revenue in the Accounting charges of $539 million were recorded R&D expenses.
Pre-tax adjustments to arrive Policy note on page 155. following analysis of relevant clinical trial data.
at Core profit before tax amounted to $2,830 In February 2016, the Group entered into a Core R&D expenses declined by 3% to $5,266 million in 2018 2017: $3,923 million, licensing agreement with CMS for the million reflecting the continued focus on comprising $2,285 million adjustments to commercialisation rights in China to Plendil resource prioritisation and productivity operating profit 2017: $3,178 million and $545 felodipine.
Under the terms of the improvements.
million to net finance expense 2017: $745 agreement, CMS paid AstraZeneca $310 million.
EBITDA increased by 6% CER: 7% to $7,140 million.
80 AstraZeneca Annual Report & Form 20-F Information 2018 Strategic Report Strategic Report Excluded from Core results were: corporate income tax rates and a $188 million programme were initially forecast to be $1.5 Restructuring expenses totalling $697 benefit from reductions of tax provisions.
billion by the end of 2017 and generate net million 2017: $807 million were largely Excluding these benefits, both the Reported annualised benefits of $1.1 billion by 2018.
The driven by $252 million fixed asset and Core tax rates would have been 21%.
total cost estimate is now $1.3 billion to be impairment and $75 million inventory write The income tax paid for the year was $537 incurred by the end of 2019, with benefits off resulting from the announcement of the million 27% of Reported profit before tax.
This expected to be $1.1 billion in 2019.
In addition US Biologics site closures in Longmont and was $594 million higher than the tax charge for to the 2016 plan, there are two further active Boulder, CO. the year as a result of certain items with no programmes.
The first is the continuation of the Amortisation totalling $1,663 million 2017: cash impact including $297 million deferred tax Phase 3 restructuring that was announced in $1,319 million relating to intangible assets, credit reflecting the reduction in Dutch and 2012, superseded by Phase 4 in 2013 and except those related to IT and to our Swedish income tax rates, $509 million of other subsequently expanded in 2014.
This initiative acquisition of BMSs share of our Global deferred tax credits, $188 million provision consists of centralisation of our global R&D Diabetes Alliance which are separately releases relating to the expiry of the statute of footprint into three strategic centres, detailed below.
Further information on our limitations and on the conclusion of tax transformation of the IT organisation, closure of intangible assets is contained in Note 9 to authority review, other net increases in a number of manufacturing facilities and other the Financial Statements from page 169. provisions for tax contingencies, partially offset activities to simplify and streamline the Intangible impairment charges of $683 by refunds following a previously disclosed organisation.
At the time of the announcement, million 2017: $488 million excluding those agreement of inter-government transfer pricing the Phase 4 programme was estimated to incur related to IT.
Further details relating to arrangements and other cash tax timing $3.2 billion of costs and deliver $1.1 billion of intangible asset impairments are included differences.
We pay corporate income taxes, annualised benefits by 2016.
By the end of inNote 9 to the Financial Statements customs duties, excise taxes, stamp duties, 2018, the Phase 4 programme had incurred frompage 169. employment and many other business taxes costs of $3.5 billion, creating headroom for Costs associated with our acquisition of inall jurisdictions where applicable.
In addition, investment in our pipeline and launch BMSs share of our Global Diabetes Alliance we collect and pay employee taxes and indirect capability.
The Phase 4 programme is now in February 2014 amounting to $277 million taxes such as value added tax.
The taxes we expected to complete in 2021, with total 2017: $954 million and included a fair value pay and collect represent a significant programme costs estimated to be $3.7 billion credit of $482 million, amortisation charges contribution to the countries and societies and annualised benefits of $1.2 billion.
of $422 million and discount unwinds in inwhich we operate.
The second step was initiated in 2016 and Other charges which includes net legal Total comprehensive income decreased by relates to multi-year transformation provisions amounted to a credit of $489 $2,516 million from the prior year, resulting programmes within our G&A functions million 2017: $355 million and was primarily in a net income of $991 million for 2018. principally Finance and HR with anticipated driven by a $352 million settlement of legal The decrease in other comprehensive income costs by the end of 2018 of $270 million.
We action in Canada in relation to patent included foreign exchange losses arising expect these transformation programmes to infringement of Losec Prilosec, recognised on designating borrowings in net investment deliver annualised benefits of $100 million by in other income.
Further details of legal hedges of $520 million 2017: gains of the end of 2019.
By the end of 2018, these proceedings in which we are currently $505 million, foreign exchange losses arising programmes had incurred costs of $304 million involved are contained within Note 29 to the on consolidation of $449 million 2017: gains with total expected costs rising to $376 million.
Financial Statements from page 194. of $536 million and net losses on equity Also included in other charges are a $208 investments measured at fair value through The aggregate restructuring charge incurred in million discount unwind charge 2017: $305 other comprehensive income of $171 million 2018 across all our restructuring programmes million and a $126 million credit 2017: $309 2017: $nil, offset by a gain on fair value was $697 million 2017: $807 million, including million for net fair value adjustments relating movements on cash flow hedges the US Biologics site closures at Longmont to contingent consideration and the Acerta transferredto profit and loss of $111 million and Boulder, CO, and other acquired assets.
Pharma put option arising on our other 2017: $315 million.
Final estimates for programme costs, benefits business combinations as detailed in Note 19 and headcount impact in all functions are to the Financial Statements from page 177.
Restructuring subject to completion of the requisite Additionally in 2017 a one-off adjustment of Since 2007, we have undertaken significant consultation in the various areas.
$617 million reflecting adjustments to efforts to restructure and reshape our deferred tax in line with the reduction to the business to improve our long-term Our priority as we undertake these US federal tax rate.
The first phases of this restructuring initiatives is to work with our restructuring, involving the integration of affected employees on the proposed Reported EPS of $1.70 in the year represented MedImmune, efficiencies within the R&D changes, acting in accordance with relevant a decline of 28% CER: 29%.
The performance function and a reduction in SG&A costs, were local consultation requirements and was driven by a decline in Externalisation completed in 2011.
The targeted commercial employment law.
Revenue and increased Cost of Sales, partly restructuring announced in 2015 has also offset by an increase in other operating income been successfully completed with a total cost and expense.
Core EPS in the year declined by of $151 million.
In 2016, we announced plans to advance our The Reported tax rate of 3 % and the Core strategy through sharper focus by streamlining tax rate in the year of 11% benefited from a operations, primarily in Commercial and favourable adjustment of $297 million to Manufacturing, to redeploy investment to deferred taxes, reflecting the recentlykeytherapy areas, particularly Oncology.
announced reductions in Dutch and Swedish Restructuring costs associated with this AstraZeneca Annual Report & Form 20-F Information 2018 Financial Review 81 Financial Review continued Brexit readiness preparations and planning Cash flow and liquidity for the year ended 31 December 2018 Following the UK referendum outcome in June Summary cash flows 2018 2017 2016 2016 for the UK to leave the EU, the UK $m $m $m Government and European Commission have Net debt brought forward at 1 January 12,679 10,657 7,762 been negotiating the terms on which the UK Profit before tax 1,993 2,227 3,552 would leave the EU and the framework for the Sum of changes in interest, depreciation, amortisation, impairment, future relationship.
While a draft Withdrawal and share of after tax losses on joint ventures and associates 5,147 4,486 3,707 Agreement has been agreed between the UK Movement in working capital and short-term provisions 639 50 926 government and the EU, at this time it remains Tax paid 537 454 412 unclear whether this will be ratified by the UK Interest paid 676 698 677 parliament in its current form, amended or if the UK will leave the EU without a deal.
In the Gains on disposal of intangible assets 1,885 1,518 1,301 absence of a ratified agreement, it is unclear Fair value movements on contingent consideration arising what trading relationships the UK will have from business combinations 495 109 1,158 with the EU and other significant trading Non-cash and other movements 290 524 492 partners after 29 March 2019 given the range Net cash inflow from operating activities 2,618 3,578 4,145 of political and legal options.
Until the Brexit Disposal purchase of intangibles net 2,010 1,082 559 negotiation process is completed, it is difficult Non-contingent payments on business combinations 1,450 2,564 to anticipate the potential impact on our market share, sales, profitability, cashflows Payment of contingent consideration from business combinations 349 434 293 and results of operations.
Other capital expenditure net 1,218 1,319 1,405 Investments 443 2,121 3,703 In response to this situation, the Group has Dividends 3,484 3,519 3,561 taken the decision to implement appropriate Share proceeds 34 43 47 actions to mitigate where possible the Distributions 3,450 3,476 3,514 potential risk of disruption to the supply of medicines including potential new medicines Other movements 65 3 177 currently undergoing clinical trials including, Net debt carried forward at 31 December 13,003 12,679 10,657 but not limited to, duplication of release testing and procedures for products based in the EU27 and the UK, transfer of regulatory Net debt reconciliation 2018 2017 2016 licences, customs and duties set up for $m $m $m introduction or amendment of existing tariffs Cash and cash equivalents 4,831 3,324 5,018 or processes and associated IT systems 1,2 Other investments 895 1,300 898 reconfiguration.
In addition, the Group has Cash and investments 5,726 4,624 5,916 engaged with its major suppliers to assess their readiness and continues to work with Overdraft and short-term borrowings 755 845 451 them to mitigate the risk of disruption to Finance leases 5 93 supply chains.
Current instalments of loans 999 1,397 1,769 Loans due after one year 17,359 15,560 14,495 The costs associated with this and certain Loans and borrowings 19,113 17,807 16,808 other actions directly related to Brexit will be charged as restructuring with the majority of Net derivative financial instruments 384 504 235 such costs expected to be cash costs.
The Net debt 13,003 12,679 10,657 current estimate of these costs is around $40 1 million.
However, until the Brexit process is Other investments in 2018 include $46 million 2017: $70 million of non-current Treasury investments.
2 Other investments include non-current investments, which are included within the balance of $833 million 2017: $933 million concluded by the UK and EU parliaments and in the Statement of Financial Position on page 150.
The equivalent GAAP measure to Net debt is liabilities arising from financing the impacts of transition to any new activities, which excludes the amounts for cash and overdrafts, other investments and non-financing derivatives shown above arrangement between them are known with and includes the Acerta Pharma put option of $1,838 million 2017: $1,823 million shown in non-current other payables.
clarity, it is difficult to anticipate the overall potential impact on the Groups operations Bonds issued in 2018 and 2017 Net book and hence the final expected costs to be value of Face value bond at 31 incurred.
Repayment of bond December dates $m $m Bonds issued in 2018: 3.5% USD bond 2023 850 845 Floating rate USD notes 2023 400 400 4% USD bond 2029 1,000 992 4.375% USD bond 2048 750 736 Total 2018 3,000 2,973 Bonds issued in 2017: 2.375% USD bond 2022 1,000 994 Floating rate USD notes 2022 250 250 3.125% USD bond 2027 750 743 Total 2017 2,000 1,987 82 AstraZeneca Annual Report & Form 20-F Information 2018 Strategic Report Strategic Report Cash flow and liquidity Financial position 31 December 2018 Net cash generated from operating activities All data in this section is on a Reported basis.
was $2,618 million in the year ended 31 December 2018, compared with $3,578 million Summary statement of financial position in 2017.
The 2018 operating cash inflows 2018 Movement 2017 Movement 2016 reflected the increase in the movement of $m $m $m $m $m working capital and short-term provisions Property, plant and equipment 7,421 194 7,615 767 6,848 impacted by the reduction of provisions Goodwill and intangible assets 33,666 4,347 38,013 1,231 39,244 relating to legal settlements, as well as Assets held for sale 982 982 launchsupport for new medicines.
Inventories 2,890 145 3,035 701 2,334 Net investment cash inflows were $443 million Trade and other receivables 6,089 233 5,856 382 5,474 2017: outflow of $2,121 million.
Trade and other payables 19,611 130 19,481 493 19,974 Provisions 891 577 1,468 50 1,418 Investment cash outflows for 2018 include Net income tax payable 957 131 826 128 954 $349 million 2017: $434 million of payments Net deferred tax liabilities 907 899 1,806 1,048 2,854 against contingent consideration arising on Retirement benefit obligations 2,511 72 2,583 397 2,186 business combinations and $328 million 2017:$294 million for the purchase of other Non-current other investments intangible assets.
2017 investment cash excluding Treasury investments of $46m in 2018 2017: $70m 787 76 863 150 713 outflows included a $1,450 million payment tothe shareholders of Acerta Pharma, a Investment in associates contractual obligation triggered by the first and joint ventures 89 14 103 4 99 regulatory approval for Calquence, following Net debt 13,003 324 12,679 2,022 10,657 on from our majority investment in Acerta Net assets 14,044 2,598 16,642 27 16,669 Pharma in 2016.
Investment cash inflows include $2,338 million 2017: $1,376 million from the sale of intangible $2,247 million.
Net debt at 31 December 2018 amortisation in the year of $2,165 million 2017: assets, including $700 million on sale of was $13,003 million, compared to $12,679 $1,829 million and the reclassification of Nexium rights in Europe to Grnenthal, $482 million at the beginning of the year, as a result assets held for sale of $982 million in respect million relating to the 2017 sale of our remaining of the cash flows as described above.
Intangible asset additions were anaesthetic portfolio to Aspen, $354 million on December 2018, cash, cash equivalents and $513 million in 2018 2017: $441 million.
the sale of Alvesco, Omnaris and Zetonna liquid investments totalled $4.8 billion and Impairment charges in the year amounted to rights outside the US to Covis Pharma, $275 undrawn committed cash facilities totalled $683 million 2017: $491 million including million from the sale of UK, China and other $4.1 billion.
international regions rights to Seroquel XR and Disposals of intangible assets totalled $339 Seroquel IR to Luye Pharma and $205 million Property, plant and equipment million in the year 2017: $307 million.
from the sale of European rights to Atacand to In 2018, Property, plant and equipment Cheplapharm.
The comparative period in 2017 decreased by $194 million to $7,421 million.
Further details of our additions to intangible included $300 million from the disposal of EU Additions of $1,034 million 2017: $1,311 assets, and impairments recorded, are rights for Seloken, $200 million from the million were offset by depreciation of $614 included in Note 9 to the Financial Statements divestment of Zomig rights outside Japan, million 2017: $624 million, impairments of from page 169.
$200 million relating to the sale of our remaining $291 million 2017: $78 million, exchange anaesthetic portfolio to Aspen and $175 million adjustments of $301 million 2017: $352 Receivables, payables and provisions regarding the Zavicefta divestment to Pfizer.
million and disposals and other movements Trade and other receivables decreased by of $22 million 2017: $194 million.
$233 million with trade receivables increasing Net cash distributions to shareholders were by $193 million to $2,995 million principally as $3,450 million 2017: $3,476 million, including Business combinations a result of higher invoiced sales in the US.
dividends of $3,484 million 2017: $3,519 In 2016, we acquired a majority equity stake in million.
Proceeds from the issue of shares on Acerta Pharma.
No business acquisitions were Trade and other payables increased by $130 the exercise of share options amounted to $34 made in 2018 or 2017.
Further details of our million in 2018 to $19,611 million.
business combinations are contained in Note was due to higher rebates in the US and China, 26 to the Financial Statements from page 186. partially offset by a deferred income release on In August 2018, we issued $3.0 billion of the Lynparza and selumetinib collaboration.
bonds in the US dollar debt capital markets Goodwill and intangible assets with maturities of five, ten and 30 years and Our goodwill of $11,707 million 2017: $11,825 The decrease in provisions of $577 million in repaid a $1.0 billion 1.75% bond and a $0.4 million principally arose on the acquisition of 2018 included a $456 million reduction on billion floating rate bond, both of which MedImmune in 2007, the restructuring of our legal provisions and a $132 million reduction matured in November 2018.
US joint venture with MSD in 1998 and the to severance provisions.
Further details of the acquisition of BMSs share of the Global charges made against provisions are At 31 December 2018, outstanding gross debt Diabetes Alliance.
contained in Notes 20 and 29 to the Financial interest-bearing loans and borrowings was Statements on page 178 and from page 194, $19,113 million 2017: $17,807 million.
Of the Intangible assets amounted to $21,959 million respectively.
gross debt outstanding at 31 December 2018, at 31 December 2018 2017: $26,188 million.
$1,754 million is due within one year 2017: The decrease was mainly driven by AstraZeneca Annual Report & Form 20-F Information 2018 Financial Review 83 Financial Review continued Contingent consideration Tax payable and receivable largely legacy arrangements as they have been The majority of our business acquisitions have Net income tax payable has increased by closed to new entrants since 2000.
In line with included elements of consideration that are $131 million 2017: decrease of $128 million to local regulations the collectively bargained contingent on future development and or $957 million, principally due to the receipt of Swedish plan is still open to employees born sales milestones, with both the Diabetes and cash in the year following a previously before 1979.
Respiratory acquisitions in 2014 also including disclosed agreement of inter-government royalty payments linked to future revenues.
transfer pricing arrangements and other cash Net retirement benefit obligations decreased The acquisitions of ZS Pharma in 2015 and tax timing differences, offset by tax provision by $72 million in 2018 2017: increase of $397 Acerta Pharma in 2016 had no contingent releases following expiry of statute of million to $2,511 million.
Net re-measurement consideration element and there were no limitations and on conclusion of tax authority adjustments of $46 million arose principally relevant acquisitions in 2017 and 2018. review.
The tax receivable balance of $207 from higher discount rate assumptions in the million 2017: $524 million principally relates to UK and US driven by rises in long-term bond Our agreement with BMS provides for cash tax timing differences.
yields which lowered the present value of the $0.6 billion in milestones and various liabilities, offset by lower than expected sales-related royalty payments up until 2025.
Net deferred tax liabilities decreased by $899 investment performance and lower discount Our transaction with Almirall includes further million 2017: $1,048 million in the year mainly rate assumptions in Sweden, where bond payments of up to $0.6 billion for future reflecting adjustments to deferred tax arising yields have fallen.
A positive $124 million development, launch, and various other from the Dutch and Swedish income tax rate impact of exchange rate movements also sales-related milestone payments, and reductions and deferred tax associated with arose in the year as the US dollar sales-related royalty payments as detailed in movements in intangible assets.
The decrease strengthened against pound sterling and Note 19 to the Financial Statements from in net deferred tax liabilities in 2017 reflected Swedish krona, reducing liability obligations in page 177. adjustments to deferred taxes in line with the US dollar terms.
Employer contributions to the reduction to the US federal income tax rate pension schemes of $174 million also All these future payments are treated as from 35% to 21% and recognition of contributed to the reduction in the net contingent consideration liabilities, and are previously unrecognised deferred tax assets.
Benefits paid fair valued using decision-tree analyses, with Additional information on the movement in amounted to $620 million 2017: $581 million.
key assumptions, including the probability of deferred tax balances is contained in Note 4 success, the potential for delays and the to the Financial Statements from page 163.
In the UK, a High Court judgement issued on expected levels of future revenues.
The fair 26 October 2018 relating to Guaranteed value is updated at each reporting date to Retirement benefit obligations Minimum Pensions GMPs is expected to reflect our latest estimate of the probabilities In terms of the Groups major defined benefit create a precedent for other UK defined of these key assumptions.
Given the longplans, approximately 91% of our total retirement benefit pension schemes and therefore is term nature of the liabilities, the fair value defined benefit obligations or around 80% of expected to increase the liabilities of the UK calculation includes the discounting of future net obligations are concentrated in the UK, the Pension Fund.
The ruling requires the potential payments to their present value US and Sweden.
The UK and US are now equalisation of member benefits to address using discount rates appropriate to the period over which payments are likely to be made.
Over time, as the target date of a Contingent consideration arising on business combinations consideration payment approaches, the 2018 2017 discount in absolute terms of such future Acquisition of Acquisition of potential payment to its present value BMSs share Other BMSs share Other decreases.
Therefore, in each period we take of Diabetes business Total of Diabetes business Total Alliance combinations 2018 Alliance combinations 2017 a corresponding charge reflecting the $m $m $m $m $m $m passage of time.
The calculation of the fair Settlements 349 349 284 150 434 value is considered to be a key estimate.
Fair value adjustments 482 13 495 208 99 109 Both the discount unwind and any movements Discount unwind 337 79 416 313 89 402 of the fair value of the underlying future At 31 December 3,983 1,123 5,106 4,477 1,057 5,534 payments can result in significant income statement movements.
As detailed in the Payments due by period Results of operations section above, these movements are treated as non-Core items in Less than Over Total Total 1 year 1-3 years 3-5 years 5 years 2018 2017 our income statement analysis.
In 2018, we $m $m $m $m $m $m recorded an interest charge of $416 million on Bank loans and the discount unwind on contingent other borrowings 2,403 4,233 3,882 17,405 27,923 25,879 consideration arising on our business Finance leases 5 combinations, and a net fair value decrease Operating leases 188 261 99 136 684 614 on contingent consideration of $495 million Contracted capital which resulted in a credit to our income expenditure 625 625 570 statement for the same amount driven, principally, by revised forecasts for revenues Total 3,216 4,494 3,981 17,541 29,232 27,068 for our Diabetes franchise.
At 31 December 1 Bank loans and other borrowings include interest charges payable in the period, as detailed in Note 27 to the Financial 2018, our contingent consideration liability Statements on page 188. was $5,106 million 2017: $5,534 million with 2 The Group has revised the presentation of operating leases from 2017 to include operating leases that have been identified the movements of the balance detailed in the during the transition to IFRS 16 as having previously been omitted from this disclosure.
This resulted in an increase in 2017 from $523 million to $614 million.
84 AstraZeneca Annual Report & Form 20-F Information 2018 Strategic Report Strategic Report gender inequality in instances where GMP Investments, divestments and In July 2013, we entered into a strategic benefits are currently unequal.
The estimated capital expenditure collaboration with FibroGen to develop and impact based on the broad profile of the UK We have completed over 260 major or commercialise roxadustat FG-4592, a Pension Fund results in a past service cost strategically important business development first-in-class oral compound in late-stage of 17 million $23 million and has been transactions over the past three years, one development for the treatment of anaemia recognised in the income statement for 2018. of which was accounted for as business associated with chronic kidney disease and acquisitions under IFRS 3 Business end-stage renal disease ESRD.
This broad The Group has undertaken several initiatives to Combinations, being the majority collaboration focuses on the US, China and reduce our net defined benefit pension investment in Acerta Pharma in 2016. all major markets excluding Japan, Europe, obligation exposure and manage the the CIS, the Middle East and South Africa, associated long-term financial risks.
As well as In addition to the business development which are covered by an existing agreement paying cash contributions when required, in the transactions detailed under Externalisation between FibroGen and Astellas.
Under the UK, a freeze on pensionable pay has been in Revenue from page 79 of this Financial arrangement, we agreed to pay FibroGen effect from 30 June 2010.
In the US, both the Review, the following significant collaborations upfront and subsequent non-contingent qualified and non-qualified US pension plans remain in the development phase: payments totalling $350 million, as well as were closed to future accrual in December potential development-related milestone 2017.
Furthermore, liability management In April 2015, we entered into two oncology payments of up to $465 million, and exercises have been carried out in the UK, agreements with Innate Pharma: firstly, a potential future sales-related milestone including a Pension Increase Exchange licence which provides us with exclusive payments, in addition to tiered royalty exercise in 2016 2017 along with improvements global rights to co-develop and payments on future sales of roxadustat in to the at retirement process to better support commercialise IPH2201 in combination with the low 20% range.
Additional development members in their retirement decisions.
Imfinzi and, secondly, an option to license milestones will be payable for any exclusive global rights to co-develop and subsequent indications which the Further details of our accounting for postcommercialise IPH2201 in monotherapy companies choose to pursue.
We will be retirement benefit plans are included in Note and other combinations in certain treatment responsible for the US commercialisation of 21 to the Financial Statements from page 178. areas.
Under the terms of the combination roxadustat, with FibroGen undertaking licence, we assumed exclusive global rights specified promotional activities in the ESRD Commitments and contingencies to research, develop and commercialise segment in this market.
The companies will We have commitments and contingencies IPH2201 in combination with Imfinzi.
We also co-commercialise roxadustat in China which are accounted for in accordance with jointly fund Phase II studies with Innate where FibroGen will be responsible for the accounting policies described in the Pharma and we lead the execution of these clinical trials, regulatory matters, Financial Statements in the Group Accounting studies.
Under the terms of the agreements, manufacturing and medical affairs, and we Policies section from page 153. we made an initial payment to Innate will oversee promotional activities and Pharma of $250 million, which included the commercial distribution.
We also have taxation contingencies.
These consideration for exclusive global rights to In March 2013, we signed an exclusive are described in the Taxation section in the co-develop and commercialise IPH2201 in agreement with Moderna to discover, Critical accounting policies and estimates combination with Imfinzi, as well as access develop and commercialise pioneering section on page 90 and in Note 29 to the to IPH2201 in monotherapy and other medicines based on messenger RNA Financial Statements from page 194. combinations in certain treatment areas.
Therapeutics for the treatment of serious The agreement includes a Phase III initiation cardiovascular, metabolic and renal Off-balance sheet transactions milestone of $100 million, as well as diseases, as well as cancer.
Under the andcommitments additional regulatory and sales-related terms of the agreement, we made an We have no off-balance sheet arrangements milestones.
We record all sales and will pay upfront payment of $240 million.
We will and our derivative activities are non-speculative.
Innate Pharma double digit royalties on net have exclusive access to select any target The table on page 84 sets out our minimum sales.
The arrangement includes the right of our choice in cardiometabolic and renal contractual obligations at the year end.
for Innate Pharma to co-promote in Europe diseases, as well as selected targets in for a 50% profit share in the territory.
oncology, over a period of up to five years Research and development In October 2018, we exercised our option for subsequent development of messenger  over IPH2201, and simultaneously entered RNA Therapeutics.
In addition, Moderna is Details of future potential R&D collaboration into a further multi-element transaction with entitled to an additional $180 million for the payments are also included in Note 29 to the Innate Pharma.
Under the agreement, we achievement of three technical milestones.
As detailed paid $50 million to collaborate on, and Through this agreement, we have the option in Note 29, payments to our collaboration acquire an option to license, IPH5201, a to select up to 40 drug products for clinical partners may not become payable due to the first-in-class anti-CD39 mAb.
Additionally, development and Moderna will be entitled inherent uncertainty in achieving the we paid $20 million to acquire options over to development and commercial milestone development and revenue milestones linked to four future programmes currently being payments as well as royalties on drug sales.
We may enter into further developed by Innate Pharma, and paid 62.6 We will lead the pre-clinical, clinical collaboration projects in the future that may million to acquire a 9.8% stake in Innate development and commercialisation of include milestone payments and, therefore, as Pharma.
The $100 million option fee and $50 therapeutics resulting from the agreement certain milestone payments fail to crystallise million have been capitalised as intangible and Moderna will be responsible for due to, for example, development not assets, along with the premium paid over designing and manufacturing the proceeding, they may be replaced by potential market price for the investment in Innate messenger RNA Therapeutics against payments under new collaborations.
The payment for future selected targets.
We are currently programmes will be expensed as research progressing 19 projects across CVRM and development expenditure over four andOncology.
At the same time, we licensed the EU expertise, significant progress has also and US rights to Lumoxiti to Innate Pharma been made with the technology platform, for $50 million upfront plus future milestone with the focus on formulation, safety, and payments of up to $25 million.
AstraZeneca Annual Report & Form 20-F Information 2018 Financial Review 85 Financial Review continued We determine the above business Dividends for 2018 $ Pence SEK Payment date development transactions to be significant First interim dividend 0.90 68.4 7.92 10 September 2018 using a range of factors.
We look at the specific circumstances of the individual Second interim dividend 1.90 146.8 17.46 27 March 2019 arrangement and apply several quantitative Total 2.80 215.2 25.38 and qualitative criteria.
Because we consider business development transactions to be an extension of our R&D strategy, the expected The Board reviews the level of distributable in initial income from externalisation and total value of development payments under reserves of the parent company annually and divestment transactions completed in 2018 the transaction and its proportion of our aims to maintain distributable reserves that and 2019, Core operating profit in 2019 is annual R&D spend, both of which are proxies provide adequate cover for dividend expected to increase at a significantly higher for overall R&D effort and cost, are important payments.
Subject to the filing of these rate, reflecting strong expected growth of the elements of the determination of the Financial Statements with the UK Companies Groups underlying business.
Other quantitative criteria we House, the distributable reserves of the parent expenditure is expected to be broadly stable apply include, without limitation, expected company as at 31 December 2018 amounts to and restructuring expenses are targeted to levels of future sales, the possible value of $13,443 million 2017: $16,715 million, details reduce compared with 2018.
A Core tax rate milestone payments and the resources used are included in the Consolidated Statement of 18% to 22% is expected for 2019. for commercialisation activities for example, of Changes in Equity on page 151.
Qualitative factors we distributable reserves are sufficient to pay These targets represent managements consider include, without limitation, new dividends for a number of years, as, when current estimates and are subject to market developments, new territories, new required, the parent company can receive change.
Please see the Cautionary areas of research and strategic implications.
dividends from its subsidiaries to increase statementregarding forward-looking distributable reserves.
Capitalisation and shareholder return Capitalisation Future prospects Financial risk management The total number of shares in issue at 31 As outlined earlier in this Annual Report, our Financial risk management policies December 2018 was 1,267 million 2017: 1,266 strategy is focused on innovation, returning to Insurance million.
0.8 million Ordinary Shares were growth and building a sustainable, durable Our risk management processes are issued upon share option exercises for a total and more profitable business.
described in Risk Overview from page 70. of $34 million.
Shareholders equity decreased These processes enable us to identify risks by $2,492 million to $12,468 million at the year In support of this, we made certain choices that can be partly or entirely mitigated through end.
Non-controlling interests were $1,576 around our three strategic priorities: the use of insurance.
We negotiate the best million 2017: $1,682 million, with the decrease available premium rates with insurance in the year as a result of the losses attributable Our immediate priorities are to continue to providers on the basis of our extensive risk to shareholders of the non-controlling interest drive Product Sales of our on-market management procedures.
We focus our in Acerta Pharma.
medicines through investment in our insurance resources on the most critical Growth Platforms and our portfolio of areas, or where there is a legal requirement, Dividend and share repurchases legacy medicines outside of the Growth and where we can get best value for money.
The Board has recommended a second Platforms.
The Growth Platforms include We purchase an external multi-line insurance interim dividend of $1.90 146.8 pence, 17.46 products in our three main therapy areas, programme to mitigate against significant SEK to be paid on 27 March 2019.
This brings and a focus on the Emerging Markets and financial loss arising from business risks the full-year dividend to $2.80 215.2 pence, Japan.
We are also pursuing business including liability, business interruption, 25.38 SEK.
Against Core earnings per share development and investment in R&D.
We property damage, and directors and officers the Group had a dividend cover ratio of 1.2:1 have already accelerated a number of liability.
In order to contain insurance costs, in 2018 2017: 1.5:1. projects and progressed them into Phase III asof February 2006, we adjusted our product development.
liability coverage profile, accepting uninsured This dividend is consistent with the Our late-stage pipeline is progressing exposure above $100 million.
progressive dividend policy, by which the ahead of plans.
Our science-driven, Board intends to maintain or grow the collaborative culture is driving increased Taxation dividend each year.
Our approach to managing tax risk is Our long-term aspiration, in line with our integrated with our broader business risk The Board regularly reviews its distribution strategic ambition, is to achieve scientific management and compliance framework.
policy and its overall financial strategy to leadership and sustainable growth.
Ourapproach is to manage tax risks and tax continue to strike a balance between the costs in a manner consistent with applicable interests of the business, our financial Full Year 2019: additional commentary regulatory requirements and with shareholders creditors and our shareholders.
Having regard In 2019, the sum of Externalisation Revenue best long-term interests, taking into account for business investment, funding the and Core other operating income and operational, economic and reputational factors.
progressive dividend policy and meeting our expense is anticipated to decline versus 2018.
We manage tax risks in the context of debt service obligations, the Board currently Core operating expenses are expected to substantive business transactions.
believes it is appropriate to continue the increase by a low single-digit percentage.
suspension of the share repurchase Specific support for medicine launches and Treasury programme which was announced in 2012.
China sales delivered compelling results in The principal financial risks to which we are 2018 and elements of that support will exposed are those arising from liquidity, continue.
The Group will retain flexibility in its interest rate, foreign currency and credit.
Core operating profit is Wehave a centralised treasury function to anticipated to increase, ahead of Product manage these risks in accordance with Sales, by a mid-teens percentage compared Board-approved policies.
Without the impact of the reduction risk is managed through maintaining access 86 AstraZeneca Annual Report & Form 20-F Information 2018 Strategic Report Strategic Report to a number of sources of funding to meet Revenue recognition Accrual assumptions are built up on a anticipated funding requirements, including Product Sales are recorded at the invoiced product-by-product and customer-bycommitted bank facilities, cash resources amount excluding inter-company sales and customer basis, taking into account specific anduse of debt factoring.
value-added taxes less movements in contract provisions coupled with expected estimated accruals for rebates and performance, and are then aggregated into a Interest rate risk is managed through chargebacks given to managed-care and other weighted average rebate accrual rate for each maintaining a debt portfolio that is weighted customers and product returns, which are a of our products.
Accrual rates are reviewed towards fixed rates of interest.
Accordingly, particular feature in the US and are considered and adjusted on an as needed basis.
There our net interest charge is not significantly to be key estimates.
It is the Groups policy to may be further adjustments when actual affected by movements in floating rates of offer a credit note for all returns and to destroy rebates are invoiced based on utilisation interest.
We monitor the impact of currency all returned stock in all markets.
Cash information submitted to us in the case of ona portfolio basis to recognise correlation discounts for prompt payment are also contractual rebates and claims invoices are effect, and may hedge to protect against deducted from sales.
Sales are recognised received in the case of regulatory rebates and significant adverse impacts on cash flow over when the control of the goods has been chargebacks.
We believe that we have made the short to medium term.
We hedge the transferred to a third party, which is usually reasonable estimates for future rebates using currency exposure that arises between the when title passes to the customer, either on a similar methodology to that of previous booking and settlement dates on non-local shipment or on receipt of goods by the years.
Inevitably, however, such estimates currency purchases and sales by subsidiaries customer depending on local trading terms.
involve judgements on aggregate future sales and the external dividend.
Significant levels, segment mix and the customers intra-group loans that give rise to foreign Rebates, chargebacks and returns in the US contractual performance.
exchange movements are also hedged.
When invoicing Product Sales in the US, we estimate the rebates and chargebacks that we Overall adjustments between gross and net US Credit risk is managed through setting and expect to pay, which are considered to be Product Sales amounted to $9,662 million in monitoring credit limits appropriate for the estimates.
These rebates typically arise from 2018 2017: $8,468 million with the increase assessed risk of the counterparty.
sales contracts with third-party manageddriven by an overall increase in our US Product care organisations, hospitals, long-term care Sales and changes in product mix.
The Group utilises factoring arrangements for facilities, group purchasing organisations and selected trade receivables.
These factoring various federal or state programmes Cash discounts are offered to customers to arrangements qualify for full derecognition of Medicaid contracts, supplemental rebates, encourage prompt payment.
Accruals are the associated trade receivables under IFRS 9 etc.
They can be classified as follows: calculated based on historical experience and Financial Instruments.
are adjusted to reflect actual experience.
Our Chargebacks, where we enter into revenue recognition policy is described within Our capital and risk management objectives arrangements under which certain parties, Group accounting policies from page 154. and policies are described in further detail in typically hospitals, long-term care facilities, Note 27 to the Financial Statements from group purchasing organisations, the Industry practice in the US allows wholesalers page 187 and in Risk Overview from page 70.
Department of Veterans Affairs, Public and pharmacies to return unused stocks Sensitivity analysis of the Groups exposure to Health Service Covered Entities and the within six months of, and up to 12 months exchange rate and interest rate movements is Department of Defense, are able to buy after, shelf-life expiry.
The customer is also detailed in Note 27 to the Financial products from wholesalers at the lower credited for the returned product by the Statements from page 189. prices we have contracted with them.
The issuance of a credit note.
Returned products chargeback is the difference between the are not exchanged for products from inventory Critical accounting policies and estimates price we invoice to the wholesaler and the and once a return claim has been determined Our Financial Statements are prepared in contracted price charged by the wholesaler to be valid and a credit note has been issued accordance with IFRS as adopted by the EU to the other party.
Chargebacks are to the customer, the returned products are adopted IFRS and as issued by the IASB, credited directly to the wholesalers.
At the point of sale in the US, we and the accounting policies employed are set Regulatory, including Medicaid and other estimate the quantity and value of products out in the Group Accounting Policies section federal and state programmes, where we which may ultimately be returned.
Our returns in the Financial Statements from page 153.
In pay rebates based on the specific terms of accruals in the US are based on actual applying these policies, we make estimates agreements with the US Department of experience.
Our estimate is based on the and assumptions that affect the Reported Health and Human Services and with historical sales and returns information for amounts of assets and liabilities and individual states, which include product established products together with marketdisclosure of contingent assets and liabilities.
usage and information on best prices and related information, such as estimated shelf The actual outcome could differ from those average market prices benchmarks.
life, product recalls, and estimated stock estimates.
Some of these policies require a Contractual, under which entities such as levels at wholesalers, which we receive via high level of judgement because the areas are third-party managed-care organisations are third-party information services.
For newly especially subjective or complex.
We believe entitled to rebates depending on specified launched products, we use rates based on that the most critical accounting policies and performance provisions, which vary from our experience with similar products or a significant areas of judgement and estimation contract to contract.
are in: The effects of these deductions on our US revenue recognition pharmaceuticals revenue and the movements research and development including on US pharmaceuticals revenue provisions impairment reviews of associated are set out overleaf.
intangibleassets business combinations and goodwill andcontingent consideration arising frombusiness combinations litigation and environmental liabilities employee benefits taxation.
AstraZeneca Annual Report & Form 20-F Information 2018 Financial Review 87 Financial Review continued Gross to net Product Sales For products facing generic competition, we US pharmaceuticals may lose the ability to estimate the levels of returns from wholesalers with the same 2018 2017 2016 degree of precision that we can for products $m $m $m still subject to patent protection.
This is Gross Product Sales 16,538 14,637 19,640 because we may have limited or no insight Chargebacks 2,224 2,299 3,449 into a number of areas: the actual timing of the Regulatory Medicaid and state programmes 1,304 1,462 1,903 generic launch for example, a generic Contractual Managed-care and Medicare 4,600 3,598 5,219 manufacturer may or may not have produced Cash and other discounts 286 30 358 adequate pre-launch inventory : the pricing and marketing strategy of the competitor: the Customer returns 119 37 130 take-up of the generic: and in cases where a US Branded Pharmaceutical Fee 140 3 145 generic manufacturer has approval to launch Other 989 1,045 1,071 only one dose size in a market of several dose Net Product Sales 6,876 6,169 7,365 sizes the likely level of switching from one dose to another.
Under our accounting policy, Movement in provisions revenue is recognised only when the amount US pharmaceuticals of the revenue is considered highly probable not to reverse.
Our approach in meeting this Brought Carried forward at Adjustment in forward at condition for products facing generic 1 January Provision for respect of Returns and 31 December competition will vary from product to product 2018 current year prior years payments 2018 depending on the specific circumstances.
$m $m $m $m $m Chargebacks 206 2,220 4 2,159 271 The adjustment in respect of prior years Regulatory Medicaid increased 2018 net US pharmaceuticals revenue and state programmes 749 1,482 178 1,161 892 by 3.2% 2017: 8.9%: 2016: 6.0%.
However, Contractual Managed-care taking into account the adjustments affecting and Medicare 1,267 4,685 85 4,325 1,542 both the current and the prior year, 2017 revenue Cash and other discounts 4 286 286 4 would have been reduced by 4.5% and 2016 Customer returns 386 119 144 361 revenue would have been increased by 1.4%, by US Branded Pharmaceutical Fee 63 99 41 151 52 adjustments between years.
Other 151 989 996 144 We have distribution service agreements with Total 2,826 9,880 218 9,222 3,266 major wholesaler buyers which serve to reduce the speculative purchasing behaviour of the Brought Carried wholesalers and reduce short-term fluctuations forward at Adjustment in forward at in the level of inventory they hold.
We do not 1 January Provision for respect of Returns and 31 December 2017 current year prior years payments 2017 offer any incentives to encourage wholesaler $m $m $m $m $m speculative buying and attempt, where Chargebacks 562 2,432 133 2,655 206 possible, to restrict shipments to underlying Regulatory Medicaid demand when such speculation occurs.
and state programmes 807 1,568 106 1,520 749 Contractual Managed-care Component revenue accounting and Medicare 1,443 3,815 217 3,774 1,267 A consequence of charging all internal R&D Cash and other discounts 6 29 1 32 4 expenditure to the income statement in the year in which it is incurred which is normal Customer returns 473 36 1 124 386 practice in the pharmaceutical industry is that US Branded Pharmaceutical Fee 260 105 108 194 63 we own valuable intangible assets which are Other 161 1,030 15 1,055 151 not recorded on the Statement of Financial Total 3,712 9,015 547 9,354 2,826 Position.
We also own acquired intangible assets which are included on the Statement of Brought Financial Position.
As detailed on page 8, our Carried forward at Adjustment in forward at business model means that, from time to time, 1 January Provision for respect of Returns and 31 December we sell such assets and generate income.
2016 current year prior years payments 2016 $m $m $m $m $m Sales of product lines are often accompanied Chargebacks 324 3,470 21 3,211 562 by an agreement on our part to continue manufacturing the relevant product for a Regulatory Medicaid and state programmes 777 1,976 73 1,873 807 reasonable period often about two years while the purchaser constructs its own Contractual Managed-care manufacturing facilities.
Details of the and Medicare 2,206 5,517 298 5,982 1,443 Externalisation Revenue accounting and the Cash and other discounts 44 358 396 6 key judgements involved are described within Customer returns 467 130 124 473 our Externalisation Revenue accounting policy US Branded Pharmaceutical Fee 264 195 50 149 260 on page 155.
Other 186 1,071 1,096 161 Total 4,268 12,717 442 12,831 3,712 88 AstraZeneca Annual Report & Form 20-F Information 2018 Strategic Report Strategic Report Research and development Future contingent elements of consideration, Litigation and environmental liabilities including impairment reviews of which may include development and launch In the normal course of business, contingent associatedintangible assets milestones, revenue threshold milestones and liabilities may arise from product-specific and Impairment reviews have been carried out on revenue-based royalties, are fair valued at the general legal proceedings, from guarantees or all intangible assets that are in development date of acquisition using decision-tree from environmental liabilities connected with and not being amortised, all major intangible analysis with key inputs including probability our current or former sites.
Where we believe assets acquired during the year and all of success, consideration of potential delays that potential liabilities have a less than 50% intangible assets that have had indications of and revenue projections based on the Groups probability of crystallising, or where we are impairment during the year.
Unsettled amounts of unable to make a reasonable estimate of the amount is determined as the higher of value in consideration are held at fair value within liability, we treat them as contingent liabilities.
use or fair value less costs to sell using a payables with changes in fair value These are not provided for, but are disclosed discounted cash flow calculation, where the recognised immediately in profit.
Several of in Note 29 to the Financial Statements products expected cash flows are riskour business combinations have included frompage 194. adjusted over their estimated remaining useful significant amounts of contingent economic life.
The determination of the consideration.
Details of the movements in the In cases that have been settled or recoverable amounts include key estimates fair value of the contingent consideration in adjudicated, or where quantifiable fines and which are highly sensitive and depend upon the year, and the range of possible contingent penalties have been assessed and which are key assumptions as detailed in Note 9 to the consideration amounts that may eventually not subject to appeal or other similar forms of Financial Statements from page 169.
Sales become payable are contained in Note 19 to relief, or where a loss is probable more than forecasts and specific allocated costs which the Financial Statements from page 177.
50% assessed probability and we are able to have both been subject to appropriate senior make a reasonable estimate of the loss, we management sign-off are risk-adjusted and Where not all the equity of a subsidiary is indicate the loss absorbed or the amount of discounted using appropriate rates based on acquired, the non-controlling interest is the provision accrued.
our post-tax weighted average cost of capital.
recognised either at fair value or at the Our weighted average cost of capital reflects non-controlling interests proportionate share Where it is considered that the Group is more factors such as our capital structure and our of the net assets of the subsidiary, on a likely than not to prevail, or in the rare costs of debt and equity.
Put options over circumstances where the amount of the legal non-controlling interests are recognised as a liability cannot be estimated reliably, legal costs The accounting for our intangible assets is financial liability measured at amortised cost, involved in defending the claim are charged to fully explained in Note 9 to the Financial with a corresponding entry in either retained profit as they are incurred.
Where it is Statements from page 169, including details earnings or against non-controlling interest considered that we have a valid contract which of the estimates and assumptions we make in reserves on a case-by-case basis.
provides the right to reimbursement from impairment testing of intangible assets.
insurance or otherwise of legal costs and or all As detailed above, we have significant or part of any loss incurred or for which a Business combinations and goodwill and investments in goodwill and intangible assets provision has been established and we contingent consideration arising from as a result of acquisitions of businesses and consider recovery to be virtually certain, then business combinations purchases of assets, such as product the best estimate of the amount expected to be Our business model includes investment in development and marketing rights.
received is recognised as an asset.
targeted business developments to strengthen our portfolio, pipeline and Details of the estimates and assumptions we Assessments as to whether or not to capabilities.
These business development make in our annual impairment testing of recognise provisions or assets and of the transactions include collaborations, asset goodwill are included in Note 8 to the amounts concerned usually involve a series of in-licences and business acquisitions.
The Group, complex judgements about future events and including acquisitions, is considered a single can rely heavily on estimates and Each transaction is considered to establish operating segment for impairment purposes.
We believe that the provisions whether it qualifies as a business combination No impairment of goodwill was identified.
recorded are adequate based on currently by applying the criteria assessment detailed in A significant portion of our investments in available information and that the insurance IFRS 3 Business Combinations.
intangible assets and goodwill arose from the recoveries recorded will be received.
restructuring of the joint venture with MSD On the acquisition of a business, fair values which commenced in 1998, the acquisition of However, given the inherent uncertainties are attributed to the identifiable assets and MedImmune in 2007 and our 2014 acquisition involved in assessing the outcomes of these liabilities and contingent liabilities unless the of BMSs interest in the Groups Diabetes cases and in estimating the amount of the fair value cannot be measured reliably, in Alliance.
In addition, our recent business potential losses and the associated insurance which case the value is subsumed into combinations, as detailed in Note 26 to the recoveries, we could in future periods incur goodwill.
Attributing fair values is a key Financial Statements from page 186, have judgments or insurance settlements that judgement.
Goodwill is the difference added significant product, marketing and could have a material adverse effect on our between the fair value of the consideration distribution intangible rights to our intangible results in any particular period.
and the fair value of net assets acquired.
We are satisfied that the value is the price that would be received to carrying values of our intangible assets as at The position could change over time, and sell an asset or pay for a liability in an orderly 31 December 2018 are fully justified by there can, therefore, be no assurance that transaction at the date of acquisition.
The estimated future cash flows.
The accounting any losses that result from the outcome of price may be directly observable but, in most for our intangible assets is fully explained in any legal proceedings will not exceed the cases, is estimated using valuation techniques Note 9 to the Financial Statements from page amount of the provisions that have been which normally involve predicting future cash 169, including details of the estimates and booked in the accounts.
flows and applying a market participant assumptions we make in impairment testing of discount rate.
Further details of our recent intangible assets.
business acquisitions are included in Note 26 to the Financial Statements from page 186.
AstraZeneca Annual Report & Form 20-F Information 2018 Financial Review 89 Financial Review continued Although there can be no assurance regarding Taxation Strategic Report The following sections make up the the outcome of legal proceedings, we do not Accruals for tax contingencies require Strategic Report, which has been prepared currently expect them to have a material management to make judgements and in accordance with the requirements of adverse effect on our financial position, but estimates of exposures in relation to tax audit the Companies Act 2006: they could significantly affect our financial issues.
Tax benefits are not recognised unless AstraZeneca at a glance results in any particular period.
the tax positions will probably be sustained Chairmans Statement based upon managements interpretation of Chief Executive Officers Review Employee benefits applicable laws and regulations and the Business model and life-cycle In relation to the Groups defined benefit likelihood of settlement.
Once considered of a medicine Marketplace pension and healthcare arrangements, we probable of not being sustained, management Strategy apply IAS 19 Employee Benefits and recognise reviews each material tax benefit to assess Key Performance Indicators all actuarial gains and losses immediately whether a provision should be taken against Business Review through other comprehensive income.
In full recognition of the benefit on the basis of Therapy Area Review Risk Overview respect of defined benefit plans, obligations potential settlement through negotiation and Financial Review are measured at discounted present value or litigation.
Accruals for tax contingencies are while plan assets are measured at fair value.
measured using the single best estimate of and has been approved and signed Given the extent of the assumptions used to likely outcome approach.
determine the values, these are considered A C N Kemp tobe key estimates.
We face a number of audits in jurisdictions Company Secretary around the world and, in some cases, are in 14 February 2019 Investment decisions in respect of defined dispute with the tax authorities.
The issues benefit schemes are based on underlying under discussion are often complex and actuarial and economic circumstances with canrequire many years to resolve.
the intention of ensuring that the schemes have sufficient assets to meet liabilities as Further details of the estimates and they fall due, rather than meeting accounting assumptions we make in determining requirements.
The local fiduciary bodies ourrecorded liability for transfer pricing which govern the investment of pension fund contingencies and other tax contingencies assets will invest across a broad range of areincluded in the Tax section of Note 29 asset classes and employ specialist tothe Financial Statements from page 194. investment managers with different investment styles.
This will ensure that the Sarbanes-Oxley Act Section 404 investment strategy is diversified across a As a consequence of our NYSE listing, we are broad range of return drivers.
In addition, local required to comply with those provisions of fiduciary bodies will also seek to hedge the Sarbanes-Oxley Act applicable to foreign liability risks interest rate and inflation risk issuers.
Section 404 of the Sarbanes-Oxley where applicable inherent in the Act requires companies annually to assess measurement of the liabilities and therefore and make public statements about the quality reduce volatility in the funding level, where this and effectiveness of their internal control over is practical and cost effective to do so.
As regards SarbanesGroup plays an active role in providing input Oxley Act Section 404, our approach is and support into these decisions.
basedon the Committee of Sponsoring Organizations COSO 2013 framework.
In assessing the discount rate applied to the obligations, we have used rates on AA Our approach to the assessment has been to corporate bonds with durations corresponding select key transaction and financial reporting to the maturities of those obligations, except in processes in our largest operating units and a Sweden where we have used rates on number of specialist areas eg financial mortgage bonds as the market in high quality consolidation and reporting, treasury corporate bonds is insufficiently deep.
In all operations and taxation etc, so that, in cases, the pension costs recorded in the aggregate, we have covered a significant Financial Statements are assessed in proportion of the key lines in our Financial accordance with the advice of independent Statements.
Each of these operating units and qualified actuaries but require the exercise of specialist areas has ensured that its relevant significant judgement in relation to assumptions processes and controls are documented to for long-term mortality, price inflation, and appropriate standards, taking into account, in future salary and pension increases.
particular, the guidance provided by the SEC.
We have also reviewed the structure and Further details of the estimates and operation of our entity level control assumptions we make in calculating postenvironment.
This refers to the overarching retirement benefit plans are included in Note control environment, including structure of 21 to the Financial Statements from page 178. reviews, checks and balances that are essential to the management of a wellcontrolled business.
90 AstraZeneca Annual Report & Form 20-F Information 2018 Strategic Report Corporate Governance Corporate Governance Chairmans Introduction 92 Corporate Governance Overview 93 Board of Directors 94 Senior Executive Team 96 Corporate GovernanceReport 98 Science Committee Report 107 Nomination and Governance Committee Report 108 Audit Committee Report 110 Directors Remuneration Report 120 AstraZeneca Annual Report & Form 20-F Information 2018 Corporate Governance 91
